Select Publications
Journal articles
, 2025, 'Implementation of precision medicine in treating non-communicable diseases: a systematic review', Journal of Translational Medicine, 23, http://dx.doi.org/10.1186/s12967-025-07201-y
, 2025, 'Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry', Nature Communications, 16, http://dx.doi.org/10.1038/s41467-025-63865-6
, 2025, 'Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action', Cancer Treatment Reviews, 140, http://dx.doi.org/10.1016/j.ctrv.2025.103013
, 2025, 'Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review.', JAMA Oncol, http://dx.doi.org/10.1001/jamaoncol.2025.3608
, 2025, 'Integration of precision medicine into routine cancer care—protocol for the Precision Care Initiative: a research programme of effectiveness-implementation hybrid trials', BMJ Open, 15, http://dx.doi.org/10.1136/bmjopen-2024-090270
, 2025, 'Federated Deep Learning Enables Cancer Subtyping by Proteomics', Cancer Discovery, 15, pp. 1803 - 1818, http://dx.doi.org/10.1158/2159-8290.CD-24-1488
, 2025, 'Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial', JAMA Oncology, 11, pp. 982 - 989, http://dx.doi.org/10.1001/jamaoncol.2025.1916
, 2025, 'A phase II trial of larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA overexpression identified by comprehensive genomic profiling', Oncologist, 30, http://dx.doi.org/10.1093/oncolo/oyae339
, 2025, 'Actionability of genomic alterations in the Molecular Screening and Therapeutics (MoST) program in New Zealand (NZ) depending on residence in NZ or Australia.', JOURNAL OF CLINICAL ONCOLOGY, 43, pp. E13763 - E13763, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.e13763
, 2025, 'Machine learning-based classification of cancer types using genomic profiling data from the Australian Molecular Screening and Therapeutics (MoST) program.', JOURNAL OF CLINICAL ONCOLOGY, 43, pp. e13683 - e13683, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.e13683
, 2025, 'Genetic predisposition in sarcomas: clinical implications and management', Eclinicalmedicine, 83, http://dx.doi.org/10.1016/j.eclinm.2025.103203
, 2025, 'Real-world characteristics and survival outcomes of patients with metastatic ALK fusion-positive solid tumors treated with standard-of-care therapies', Oncologist, 30, http://dx.doi.org/10.1093/oncolo/oyaf005
, 2025, 'Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma', BMJ Open, 15, pp. e087922, http://dx.doi.org/10.1136/bmjopen-2024-087922
, 2025, 'High-throughput 3D engineered paediatric tumour models for precision medicine', Molecular Systems Biology, http://dx.doi.org/10.1038/s44320-025-00152-y
, 2025, 'Oncogenic mutations in the TP53 and PI-3 kinase/AKT pathway are independent predictors of survival for advanced thyroid cancer: Analysis from the Molecular Screening and Therapeutics (MoST) program', Surgery United States, 177, http://dx.doi.org/10.1016/j.surg.2024.05.058
, 2025, 'POT1 clinical risk management is an open question', European Journal of Human Genetics, 33, pp. 3 - 4, http://dx.doi.org/10.1038/s41431-024-01676-x
, 2025, 'Precision Oncology: A Global Perspective on Implementation and Policy Development', JCO Global Oncology, 11, http://dx.doi.org/10.1200/GO-24-00416
, 2025, 'Australasian Bronchiolitis Guideline: 2025 Update', JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 61, pp. 1197 - 1215, http://dx.doi.org/10.1111/jpc.70144
, 2025, 'Clinical and economic value of comprehensive genomic profiling in patients with advanced solid cancers using Australian real-world data: Preliminary analyses.', Journal of Clinical Oncology, 43, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.e15084
, 2025, 'Genomic and outcome analysis of recurrent versus de novo metastatic pancreatic ductal adenocarcinoma (PDAC) receiving systemic therapy: Results from the Australian MoST and CaSP screening programs.', Journal of Clinical Oncology, 43, pp. 4120 - 4120, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.4120
, 2025, 'Population-based assessment of leiomyosarcoma (LMS) and cancers in the Li-Fraumeni syndrome (LFS) spectrum: Implications for genetic testing criteria.', Journal of Clinical Oncology, 43, pp. 11570 - 11570, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.11570
, 2024, 'A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation', Npj Precision Oncology, 8, http://dx.doi.org/10.1038/s41698-024-00698-4
, 2024, 'Connecting the changing trace elements spectrum and survival in sarcoma: a pilot study', Metabolomics, 20, http://dx.doi.org/10.1007/s11306-024-02178-z
, 2024, 'Correction to: IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting (Nature Communications, (2017), 8, 1, (14607), 10.1038/ncomms14607)', Nature Communications, 15, http://dx.doi.org/10.1038/s41467-024-53456-2
, 2024, 'Topological barrier to Cas12a activation by circular DNA nanostructures facilitates autocatalysis and transforms DNA/RNA sensing', Nature Communications, 15, pp. 1818, http://dx.doi.org/10.1038/s41467-024-46001-8
, 2024, 'Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma', Cancer Epidemiology, 92, http://dx.doi.org/10.1016/j.canep.2023.102432
, 2024, 'From ownership to custodianship of tumor biopsy tissue in genomic testing: A mixed methods study of patient views', Oncologist, 29, pp. e1169 - e1179, http://dx.doi.org/10.1093/oncolo/oyae074
, 2024, 'Atezolizumab in patients (pts) with tumor mutational burden (TMB)-high tumors from the TAPISTRY trial.', JOURNAL OF CLINICAL ONCOLOGY, 42, pp. LBA2509 - LBA2509, http://dx.doi.org/10.1200/JCO.2024.42.17_suppl.LBA2509
, 2024, 'Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development', Cancer Cell, 42, pp. 923 - 929, http://dx.doi.org/10.1016/j.ccell.2024.05.014
, 2024, 'Ipatasertib in patients with AKT1/2/3 mutation-positive (AKTmut) tumors: TAPISTRY study.', Journal of Clinical Oncology, 42, pp. 3092 - 3092, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3092
, 2024, 'Underlying germline genetic architecture of pediatric sarcomas: Evaluating the role of common and rare variants in 4,160 patients', CANCER RESEARCH, 84, http://dx.doi.org/10.1158/1538-7445.AM2024-775
, 2024, 'National Health and Medical Research Council statement on electronic cigarettes: 2022 update', Medical Journal of Australia, 220, pp. 100 - 106, http://dx.doi.org/10.5694/mja2.52163
, 2024, 'Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23–24, 2023', Molecular Oncology, 18, pp. 245 - 279, http://dx.doi.org/10.1002/1878-0261.13575
, 2024, 'ASPiRATION: Australian Observational Cohort Study of Comprehensive Genomic Profiling in Metastatic Lung Cancer Tissue', Future Oncology, 20, pp. 361 - 371, http://dx.doi.org/10.2217/fon-2023-0366
, 2024, 'Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum', JCO Precision Oncology, 8, http://dx.doi.org/10.1200/PO.23.00453
, 2024, 'Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation framework', Therapeutic Advances in Medical Oncology, 16, http://dx.doi.org/10.1177/17588359241273062
, 2024, 'Increased frequency of CHEK2 germline pathogenic variants among individuals with dermatofibrosarcoma protuberans', Genetics in Medicine Open, 2, http://dx.doi.org/10.1016/j.gimo.2024.101895
, 2024, '282P Nivolumab and ipilimumab combination treatment in advanced intrahepatic cholangiocarcinoma and gallbladder cancer', Annals of Oncology, 35, pp. S119 - S119, http://dx.doi.org/10.1016/j.annonc.2024.05.288
, 2024, '998MO Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study', Annals of Oncology, 35, pp. S679 - S680, http://dx.doi.org/10.1016/j.annonc.2024.08.1057
, 2024, 'Computational repurposing of oncology drugs through off-target drug binding interactions from pharmacological databases', CLINICAL AND TRANSLATIONAL MEDICINE, 14, http://dx.doi.org/10.1002/ctm2.1657
, 2024, 'Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trial', ANNALS OF ONCOLOGY, 35, pp. S546 - S547, http://dx.doi.org/10.1016/j.annonc.2024.08.775
, 2023, 'A pan-sarcoma landscape of telomeric content shows that alterations in RAD51B and GID4 are associated with higher telomeric content', Npj Genomic Medicine, 8, http://dx.doi.org/10.1038/s41525-023-00369-6
, 2023, 'Precision medicine: affording the successes of science', Npj Precision Oncology, 7, http://dx.doi.org/10.1038/s41698-022-00343-y
, 2023, 'Ligand-dependent hedgehog signaling maintains an undifferentiated, malignant osteosarcoma phenotype', Oncogene, 42, pp. 3529 - 3541, http://dx.doi.org/10.1038/s41388-023-02864-7
, 2023, 'PATH-25. EXPLORING THE PROGNOSTIC IMPLICATIONS OF MOLECULAR ALTERATIONS IN ASTROCYTOMAS USING COMPREHENSIVE GENOMIC PROFILING (CGP)', Neuro-Oncology, 25, pp. v173 - v173, http://dx.doi.org/10.1093/neuonc/noad179.0655
, 2023, 'Modified study designs to expand treatment options in personalised oncology: a multistakeholder view', European Journal of Cancer, 194, http://dx.doi.org/10.1016/j.ejca.2023.113278
, 2023, 'Myelodysplastic syndrome and multiple solid tumours in an individual with compound heterozygous deleterious FANCM variants: A case report and review of the literature', British Journal of Haematology, 203, pp. 481 - 484, http://dx.doi.org/10.1111/bjh.19059
, 2023, 'Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials', International Journal of Cancer, 153, pp. 1413 - 1422, http://dx.doi.org/10.1002/ijc.34649
, 2023, 'Family communication and results disclosure after germline sequencing: A mixed methods study', Patient Education and Counseling, 114, http://dx.doi.org/10.1016/j.pec.2023.107800
, 2023, 'Implementation of the Australasian Teletrial Model: Translating ideas into action using implementation science frameworks', Journal of Telemedicine and Telecare, 29, pp. 641 - 647, http://dx.doi.org/10.1177/1357633X211017805